Catherine A Chappell1, Charles E Isaacs2, Weimin Xu2, Leslie A Meyn3, Kevin Uranker3, Charlene S Dezzutti4, Bernard J Moncla4, Sharon L Hillier4. 1. Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: chappellca@upmc.edu. 2. Department of Developmental Biochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY. 3. Magee-Womens Research Institute, Pittsburgh, PA. 4. Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Magee-Womens Research Institute, Pittsburgh, PA.
Abstract
OBJECTIVE: Reproductive hormones are known to impact innate mucosal immune function of the lower genital tract. Our objectives were to determine the effect of hormonal status on intrinsic antiviral (herpes simplex virus [HSV]-1, HSV-2, and human immunodeficiency virus [HIV]-1) activity of cervicovaginal lavage (CVL). STUDY DESIGN: CVL was collected from 165 asymptomatic women including postmenopausal women (n = 29); women not on contraception in days 1-14 (n = 26) or days 15-28 (n = 27) of the menstrual cycle; and women using the levonorgestrel intrauterine device (n = 28), depot medroxyprogesterone acetate (n = 28), or combined oral contraceptives (n = 27). The anti-HSV-1/-2 and the anti-HIV-1 activity of the CVL were measured using plaque assays and the Jurkat-Tat-CCR5 assay, respectively. RESULTS: CVL from all of the groups had modest antiviral activity. Anti-HIV-1 activity was decreased in CVL from postmenopausal women when compared to premenopausal women (11% vs 34%, P = .002). However, there was no difference in anti-HIV-1 activity among premenopausal women regardless of phase of menstrual cycle or contraceptive use. Anti-HIV-1 activity was associated with the protein content of the CVL (r = 0.44, P < .001). There was no difference in anti-HSV-1 or -2 activity by hormonal group. CONCLUSION: Menopause is associated with decreased innate HIV-1 activity in the lower genital tract, suggesting that factors in the vaginal fluid could play a role in increased susceptibility of HIV-1 infection in postmenopausal women. Hormonal contraceptive use, menopause, and phase of menstrual cycle did not have a measurable impact on the intrinsic anti-HSV-1 or -2 activity.
OBJECTIVE: Reproductive hormones are known to impact innate mucosal immune function of the lower genital tract. Our objectives were to determine the effect of hormonal status on intrinsic antiviral (herpes simplex virus [HSV]-1, HSV-2, and human immunodeficiency virus [HIV]-1) activity of cervicovaginal lavage (CVL). STUDY DESIGN: CVL was collected from 165 asymptomatic women including postmenopausal women (n = 29); women not on contraception in days 1-14 (n = 26) or days 15-28 (n = 27) of the menstrual cycle; and women using the levonorgestrel intrauterine device (n = 28), depot medroxyprogesterone acetate (n = 28), or combined oral contraceptives (n = 27). The anti-HSV-1/-2 and the anti-HIV-1 activity of the CVL were measured using plaque assays and the Jurkat-Tat-CCR5 assay, respectively. RESULTS: CVL from all of the groups had modest antiviral activity. Anti-HIV-1 activity was decreased in CVL from postmenopausal women when compared to premenopausal women (11% vs 34%, P = .002). However, there was no difference in anti-HIV-1 activity among premenopausal women regardless of phase of menstrual cycle or contraceptive use. Anti-HIV-1 activity was associated with the protein content of the CVL (r = 0.44, P < .001). There was no difference in anti-HSV-1 or -2 activity by hormonal group. CONCLUSION: Menopause is associated with decreased innate HIV-1 activity in the lower genital tract, suggesting that factors in the vaginal fluid could play a role in increased susceptibility of HIV-1 infection in postmenopausal women. Hormonal contraceptive use, menopause, and phase of menstrual cycle did not have a measurable impact on the intrinsic anti-HSV-1 or -2 activity.
Authors: Brenna L Anderson; Mimi Ghosh; Christina Raker; John Fahey; Yan Song; Dwight J Rouse; Charles R Wira; Susan Cu-Uvin Journal: Am J Obstet Gynecol Date: 2012-04-30 Impact factor: 8.661
Authors: Amie L Meditz; Kerrie L Moreau; Samantha MaWhinney; Wendolyn S Gozansky; Kelsey Melander; Wendy M Kohrt; Margaret E Wierman; Elizabeth Connick Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: Renee Heffron; Deborah Donnell; Helen Rees; Connie Celum; Nelly Mugo; Edwin Were; Guy de Bruyn; Edith Nakku-Joloba; Kenneth Ngure; James Kiarie; Robert W Coombs; Jared M Baeten Journal: Lancet Infect Dis Date: 2011-10-03 Impact factor: 25.071
Authors: Mickey V Patel; Mimi Ghosh; John V Fahey; Christina Ochsenbauer; Richard M Rossoll; Charles R Wira Journal: Am J Reprod Immunol Date: 2014-05-08 Impact factor: 3.886
Authors: Charles R Wira; John V Fahey; Marta Rodriguez-Garcia; Zheng Shen; Mickey V Patel Journal: Am J Reprod Immunol Date: 2014-04-16 Impact factor: 3.886
Authors: Catherine A Chappell; Lisa C Rohan; Bernard J Moncla; Lin Wang; Leslie A Meyn; Katherine Bunge; Sharon L Hillier Journal: Am J Obstet Gynecol Date: 2014-03-21 Impact factor: 8.661
Authors: Timothy Lahey; Mimi Ghosh; John V Fahey; Zheng Shen; Lucy R Mukura; Yan Song; Susan Cu-Uvin; Kenneth H Mayer; Peter F Wright; John C Kappes; Christina Ochsenbauer; Charles R Wira Journal: PLoS One Date: 2012-06-04 Impact factor: 3.240
Authors: Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Jared M Baeten; Joelle Brown; Angela M Crook; Lut Van Damme; Sinead Delany-Moretlwe; Suzanna C Francis; Barbara A Friedland; Richard J Hayes; Renee Heffron; Saidi Kapiga; Quarraisha Abdool Karim; Stephanie Karpoff; Rupert Kaul; R Scott McClelland; Sheena McCormack; Nuala McGrath; Landon Myer; Helen Rees; Ariane van der Straten; Deborah Watson-Jones; Janneke H H M van de Wijgert; Randy Stalter; Nicola Low Journal: PLoS Med Date: 2015-01-22 Impact factor: 11.069
Authors: Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-02-10 Impact factor: 2.205
Authors: Andrea Ries Thurman; Nazita Yousefieh; Neelima Chandra; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy C Herold; Jamie L Freiermuth; Brian S Starkman; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Sharon Hillier; Lorna Rabe; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2017-05-16 Impact factor: 2.205
Authors: Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752
Authors: Beatrice A Chen; Jingyang Zhang; Holly M Gundacker; Craig W Hendrix; Craig J Hoesley; Robert A Salata; Charlene S Dezzutti; Ariane van der Straten; Wayne B Hall; Cindy E Jacobson; Sherri Johnson; Ian McGowan; Annalene M Nel; Lydia Soto-Torres; Mark A Marzinke Journal: Clin Infect Dis Date: 2019-03-19 Impact factor: 9.079
Authors: Patti E Gravitt; Morgan Marks; Margaret Kosek; Christine Huang; Lilia Cabrera; Maribel Paredes Olortegui; Alberto Mejia Medrano; Dixner R Trigoso; Sarah Qureshi; Gustavo S Bardales; Javier Manrique-Hinojosa; Albert Z Cardenas; Manuel A Larraondo; Jaime Cok; Fares Qeadan; Mark Siracusa; Robert H Gilman Journal: J Infect Dis Date: 2015-10-20 Impact factor: 5.226
Authors: Caroline M Mitchell; Nanxun Ma; Alissa J Mitchell; Michael C Wu; D J Valint; Sean Proll; Susan D Reed; Katherine A Guthrie; Andrea Z Lacroix; Joseph C Larson; Robert Pepin; Daniel Raftery; David N Fredricks; Sujatha Srinivasan Journal: Am J Obstet Gynecol Date: 2021-03-04 Impact factor: 10.693